Sedgwick M L, Lip G, Rae A P, Cobbe S M
Department of Medical Cardiology, Royal Infirmary, Glasgow, UK.
Int J Cardiol. 1995 Apr;49(2):159-66. doi: 10.1016/0167-5273(95)02284-4.
We studied the effects of two active dose levels of dofetilide (8 and 12 micrograms/kg) and placebo in 16 patients with recent onset atrial fibrillation. The study was of a crossover design such that all patients received a therapeutic agent, 15 patients completed the study. Cardioversion was achieved in 2/6 patients receiving 8 micrograms/kg dofetilide and in 2/9 patients receiving 12 micrograms/kg. No patients cardioverted as a result of the placebo infusion. Two patients who cardioverted suffered episodes of torsades de pointes following the active drug. Electrical cardioversion was attempted in eight patients who remained in atrial fibrillation and was successful in six. The average duration of atrial fibrillation was 35 days in those who cardioverted and 83 days in those who did not. The compound appears to have only limited effect in cardioversion of atrial fibrillation of moderate duration.
我们研究了两种活性剂量（8微克/千克和12微克/千克）的多非利特及安慰剂对16例近期发作房颤患者的影响。该研究采用交叉设计，所有患者均接受一种治疗药物，15例患者完成了研究。接受8微克/千克多非利特的6例患者中有2例实现了心脏复律，接受12微克/千克的9例患者中有2例实现了心脏复律。没有患者因输注安慰剂而实现心脏复律。2例实现心脏复律的患者在使用活性药物后发生了尖端扭转型室速。对8例仍处于房颤状态的患者尝试进行电复律，其中6例成功。实现心脏复律的患者房颤平均持续时间为35天，未实现心脏复律的患者房颤平均持续时间为83天。该化合物对中度持续时间房颤的复律作用似乎有限。
